Purpose: Women with breast cancer were randomized to receive coenzyme Q10 (CoQ10) plus Vitamin E or placebo in a clinical trial. The objective of this evaluation is to examine the association between participant self-reported adherence to the study supplements and changes in plasma biomarker levels.
Patients and methods: Correlation coefficients quantified the association between changes in alpha-tocopherol and CoQ10 levels and the association between self-reported adherence and changes in biomarkers. Participants were categorized by self-reported adherence; Kruskal- Wallis tests compared changes in alpha-tocopherol and CoQ10 levels between self-reported adherence groups.
Results: Women (N=155) provided baseline and post-treatment biomarkers; 147 completed at least one diary. While changes in alpha-tocopherol and CoQ10 levels were moderately correlated, correlations ranged from 0.40 to 0.48, association between self-reported adherence and plasma alpha-tocopherol or CoQ10 levels was weak; correlations ranged from 0.10 to 0.29 at weeks 8, 16, and 24. Some participants with high self-reported adherence actually had decreases in their biomarker levels.
Conclusion: These findings support that self-reported adherence is likely to be overestimated. Biological and other measures of adherence that can better identify true adherence to study pills provided in clinical trials are greatly needed as they may assist in improving the interpretation of findings of future clinical trials.
Keywords: CoQ10; adherence; alpha-tocopherol; blood biomarkers; clinical trial; self-report.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer.J Support Oncol. 2013 Mar;11(1):31-42. doi: 10.1016/j.suponc.2012.03.003. J Support Oncol. 2013. PMID: 22682875 Free PMC article. Clinical Trial.
Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2014;(12):CD010405. doi: 10.1002/14651858.CD010405.pub2. Epub 2014 Dec 4. Cochrane Database Syst Rev. 2014. PMID: 25474484 Review.
Plasma vitamin E and coenzyme Q10 are not associated with a lower risk of acute myocardial infarction in Singapore Chinese adults.J Nutr. 2012 Jun;142(6):1046-52. doi: 10.3945/jn.111.155341. Epub 2012 Apr 18. J Nutr. 2012. PMID: 22513986 Free PMC article.
Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial.Am J Kidney Dis. 2017 Mar;69(3):389-399. doi: 10.1053/j.ajkd.2016.08.041. Epub 2016 Dec 4. Am J Kidney Dis. 2017. PMID: 27927588 Free PMC article. Clinical Trial.
Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis.J Clin Pharm Ther. 2015 Aug;40(4):413-8. doi: 10.1111/jcpt.12280. Epub 2015 Apr 25. J Clin Pharm Ther. 2015. PMID: 25913756 Review.
- Dunbar-Jacob JM, Schlenk EA, Burke LE, Matthews JT. Predictors of patient adherence: patient characteristics. In: Schumaker SA, Schron EB, Ockene JK, McBee WL, editors. The Handbook of Health Behavior Change. 2nd ed. New York, NY: Springer; 1998. pp. 491–511.
- Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 4th ed. New York, NY: SpringerVerlag; 2010.
- Lasagna L, Hutt PB. Health care, research and regulatory impact of noncompliance. In: Cramer JA, Spilker B, editors. Patient Compliance in Medical Practice and Clinical Trials. New York, NY: Raven Press; 1991. pp. 393–403.
- Burney KD, Krishnan K, Ruffin MT, Zhan D, Brenner DE. Adherence to single daily dose of aspirin in a chemoprevention trial: an evaluation of self-report and micro-electronic monitory. Arch Fam Med. 2009;5(5):297–300. - PubMed
- Cramer JA. Patient compliance in medical practice and clinical trials. In: Cramer JA, Spilker B, editors. Patient Compliance in Medical Practice and Clinical Trials. New York, NY, USA: Raven Press; 1991. pp. 3–10.